New formulation of ddI approved in Canada--Videx EC.
D002170:Canada; D016049:Didanosine / Q000008:administration & dosage / Q000627:therapeutic use; D004304:Dosage Forms; D017277:Drug Approval; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use
D004304:Dosage Forms; D018894:Reverse Transcriptase Inhibitors; D016049:Didanosine